Clinical Trials Browser

Interventional × Breast Neoplasms × bosutinib × Clear all

NCT03854903 2025-02-06

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00880009 2021-09-27

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

Phase 2 Terminated

16 enrolled 6 charts

Breast Neoplasms

NCT00319254 2013-01-31

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

Phase 2 Completed

75 enrolled 13 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00793546 2012-11-05

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

Phase 2 Terminated

42 enrolled 7 charts

Breast Neoplasms

NCT00759837 2009-07-16

Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects

Phase 1 Completed

BreastMyeloidOther hematologic neoplasm

Breast Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00777530 2008-10-23

Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects

Phase 1 Completed

BreastOther hematologic neoplasm

Breast Neoplasms, Leukemia, Neoplasms